RS Research is a pharmaceutical company developing next generation of nanomedicines based on an innovative drug delivery platform.
RS Research is a clinical-stage biotechnology start-up developing novel nanomedicines. We have discovered a novel drug delivery platform with which we currently have development programs in various preclinical and clinical stages for therapies to treat patients fighting cancer.Our nanocarrier platform (Sagitta®) is highly tunable with a plug & play approach, allowing rapid development of targeted nanomedicines with superior performance aiming multiple indications.Along with moving our own candidates toward clinic, we provide preclinical services to industrial and academic partners. We have specific expertise in biosimilar characterization as well as in vivo experiment design and implementation. Our GMP certified production facility is the first cytotoxic-capable clinical batch-size contract organization for such services in the region.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 15, 2021 | Series A | $12M | 3 | Gen Pharmaceuticals | — | Detail |
Jan 10, 2018 | Convertable Note | €0.90M | 1 | ACT Venture Partners | — | Detail |
Apr 21, 2017 | Seed | €1.10M | 1 | ACT Venture Partners | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Gen Pharmaceuticals | Yes | Series A |
ACT Venture Partners | Yes | Convertable Note |
Eczacıbasi Momentum | — | Series A |
İstanbul Portföy Yönetimi | — | Series A |